#None #AJ201 #SBMA #AnnJi

AnnJi Pharmaceutical Advances AJ201 into Phase 3 ROMA-KD Trial for SBMA

Introduction

In a major stride for the treatment of spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's disease, AnnJi Pharmaceutical Co., Ltd. has announced the progression of AJ201, an investigational oral medication, into pivotal Phase 3 clinical trials. This marks the only known investigational therapy for SBMA currently in Phase 3 development worldwide.

Understanding SBMA

SBMA is a rare genetic neuromuscular disorder characterized by progressive weakness and atrophy of both the spinal and bulbar muscles. It predominantly affects males and results from a mutation in the androgen receptor gene, leading to motor neuron degeneration and muscle wasting. Despite the significant impact on daily life—ranging from difficulty in climbing stairs, eating, and speaking—there is no FDA-approved treatment available to halt or reverse the disease's progression.

The Clinical Importance of AJ201

AJ201, also known as rosolutamide, is designed to target various mechanisms responsible for SBMA. This small molecule works by promoting the clearance of mutated androgen receptors while simultaneously activating cellular stress-response pathways. Results from a previous Phase 2 study, announced in May 2025, revealed promising outcomes, prompting the move into the larger Phase 3 program.

Dr. Wendy Huang, Chairperson and CEO of AnnJi, emphasized the importance of AJ201, stating, “For people living with SBMA, the disease is felt in everyday moments... advancing AJ201 into Phase 3 brings us one step closer to potentially changing that.” The Phase 3 ROMA-KD trial aims to comprehensively evaluate the safety and efficacy of AJ201, including enrolling approximately 200 patients globally, with the U.S. being a central participant.

Trial Design and Objectives

The ROMA-KD trial is structured as a randomized, double-blind, placebo-controlled study. It is not only aimed at determining the therapeutic efficacy of AJ201 but also structured to support potential global regulatory submissions. The activation of trial sites across the U.S. will be a priority for AnnJi, as they work to recruit eligible patients responsibly and ethically.

Advisory Council Initiative

In conjunction with this trial, AnnJi has launched an SBMA Patient and Care Partner Advisory Council. This Council, in collaboration with the Kennedy's Disease Association, is designed to gather insights from those living with SBMA and their caregivers. Their experiences will inform patient-centered clinical development and research, ensuring that the needs and perspectives of the community are central to the drug’s development process.

Commitment to Patient-Centric Research

AnnJi’s commitment extends beyond the clinical trials. The company aims to foster transparent collaborations with patients, families, and healthcare providers as they continue the journey to develop effective treatments for SBMA. This partnership approach is pivotal in shaping clinical research and promoting shared knowledge.

Conclusion

As AnnJi Pharmaceutical moves forward with the Phase 3 ROMA-KD trial of AJ201, the future for individuals impacted by SBMA shines with potential hope. The developments signify not only scientific advancements but also a commitment to bettering patients' lives by addressing an urgent medical need. The outcome of this trial could pave the way for an unprecedented therapeutic option, revolutionizing the management of SBMA and changing the lives of patients and their families for the better.

AJ201 stands as a beacon of hope for the SBMA community, representing a promise of innovation and care in the face of a challenging and often overlooked condition.